Incyte Corp (NASDAQ:INCY)

94.36
Delayed Data
As of Mar 27
 +5.16 / +5.78%
Today’s Change
40.30
Today|||52-Week Range
99.00
+29.07%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$16.2B

Company Description

Incyte Corp. is a biopharmaceutical company. It focuses on the discovery, development and commercialization of proprietary small molecule drugs to treat serious unmet medical needs. The company's product, Jakafi (ruxolitinib), a JAK1 and JAK2 inhibitor, is currently approved in the U.S. for the treatment of intermediate or high-risk myelofibrosis and is in development as a potential treatment for other cancers. Incyte was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Contact Information

Incyte Corp.
Experimental Station
Wilmington Delaware 19880
P:(302) 498-6700
Investor Relations:
(302) 498-6944

Employees

Shareholders

Mutual fund holders63.65%
Other institutional34.54%
Individual stakeholders12.38%

Top Executives

Hervé HoppenotPresident, Chief Executive Officer & Director
David W. GryskaChief Financial Officer & Executive Vice President
Reid M. HuberChief Scientific Officer & Executive VP
Steven H. SteinChief Medical Officer & Senior Vice President
Richard S. LevyChief Drug Development Officer & Executive VP

To view my watchlist

Not a member yet?

Sign up now for a free account